Vyepti® (eptinezumab-jjmr)

Vyepti (eptinezumab‑jjmr) is covered only for the FDA‑approved preventive treatment of migraine in adults and is excluded for patients <18 years, for indications other than migraine prevention, for those with <4 migraine days/month at baseline, or for concurrent use with another CGRP inhibitor. Approval is for 12 months with recommended dosing 100 mg IV every 3 months and requires documentation of age ≥18, ≥4 baseline migraine days/month, no current CGRP inhibitor use, administration/dosing records, and—for renewals—documented significant clinical benefit (reduction in overall or severe migraine days).

"Vyepti is indicated for the preventive treatment of migraine in adults."

Sign up to see full coverage criteria, indications, and limitations.